Steroid treatment alters adhesion molecule and chemokine expression in experimental acute graft-vs.-host disease of the intestinal tract

Bouazzaoui, Abdellatif; Spacenko, Elena; Mueller, Gunnar; Huber, Elisabeth; Schubert, Thomas; Holler, Ernst; Andreesen, Reinhard

doi:10.1016/j.exphem.2010.11.006

Cited by 28 publications

(24 citation statements)

References 67 publications

(109 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…109 Steroid therapy may affect chemokine levels such as CXCL 9–11 and CCL2–3 , and, due to differential expression, the recruitment of T-cells to gut but not liver. 110 Although there is no direct evidence from animal studies on the role of CCR9 in GVHD, CCR9 polymorphisms have been linked to GVHD severity in humans, 111 making it a potential target for future clinical trials. However, one limitation of the use of chemokine receptor antagonists, such as CCR5, is the possible interference with TReg recruitment to GVHD target organs 105 .…”

Section: Targeting T-cell Homingmentioning

confidence: 99%

Advances in graft-versus-host disease biology and therapy

2012

View full text Add to dashboard Cite

Preface Allogeneic haematopoietic stem cell transplantation is used to treat a variety of disorders, but its efficacy is limited by the occurrence of graft-versus-host disease (GVHD). The past decade has brought impressive advances in our understanding of the role of both donor and host adaptive and innate immune stimulatory and immune suppressive factors that influence GVHD pathogenesis. New insights in basic immunology, preclinical models and clinical studies have led to novel prevention or treatment approaches. This review highlights recent advances in GVHD pathophysiology and its treatment with a focus on immune system manipulations that are amenable to clinical application.

show abstract

Section: Targeting T-cell Homingmentioning

confidence: 99%

Advances in graft-versus-host disease biology and therapy

2012

View full text Add to dashboard Cite

show abstract

“…Clinical GVHD scores were assessed weekly by a scoring system incorporating five clinical parameters: weight loss, posture (hunching), mobility, fur texture and skin integrity 21 . Each parameter was graded between 0 and 2.…”

Section: Transplantation Proceduresmentioning

confidence: 99%

“…Detailed analysis of changes in GI tract, liver, lung and skin histology was performed in a blinded fashion as previously described 21 . Analysis was performed by light microscopy (Axioskop 2 plus, Carl Zeiss GmbH, Jena, Germany).…”

Section: Transplantation Proceduresmentioning

confidence: 99%

See 1 more Smart Citation

Cytostatic conditioning in experimental allogeneic bone marrow transplantation: Busulfan causes less early gastrointestinal toxicity but Treosulfan results in improved immune reconstitution

Bouazzaoui¹,

Dickhöfer²,

Kreuz³

et al. 2014

Immunopharmacology and Immunotoxicology

Self Cite

View full text Add to dashboard Cite

show abstract

“…On account of the differences in donor, host, and transplantation characteristics in mice and humans (ie, different conditioning regimens, cell sources, genetic and immunological matches, host microbiome, and age), the results of murine models cannot be fully aligned with the results in humans [29]. Moreover, further cell sets, eg, host antigen-presenting cells, cytokine modulation, and also tissue response to GC play a role in the complex interplay of host and donor immunity in human aGVHD [30][31][32]. Our findings warrant further validation of the genetic determinants of response to GC in donor and recipient pairs both in functional assays and in a larger cohort.…”

Section: Discussionmentioning

confidence: 84%

GLCCI1 and Glucocorticoid Receptor Genetic Diversity and Response to Glucocorticoid-Based Treatment of Graft-versus-Host Disease

O'Meara¹,

Boukouaci²,

Robin³

et al. 2015

Biology of Blood and Marrow Transplantation

View full text Add to dashboard Cite

The genetic diversity of loci implicated in glucocorticoid (GC) response has been associated with interindividual variations in responsiveness to GC in various diseases, such as asthma and inflammatory bowel disorders. In acute graft-versus-host disease (aGVHD), similar differences of first-line therapy responsiveness are also observed, with approximately 40% of patients failing to respond to GC. Here, the distribution of functionally relevant single nucleotide polymorphisms (SNP) belonging to the GC-induced transcript 1 GLCCI1 (rs37972) and the glucocorticoid receptor (rs41423247, rs6195 and rs6198) gene loci were analyzed alongside clinical factors for their association with the response to corticosteroids in aGVHD. The frequencies of variant alleles did not differ significantly between corticoresistant patients, their donors, and their corticosensitive peers (P = .10 to 1.00). Severe and early onset of aGVHD, bone marrow as the stem cell source, and an HLA mismatch were associated with the failure to respond to GC in logistic regression. After including the single SNPs to the model, carriers of the rs41423247 polymorphism had a higher probability of responding to GC, whereas all other polymorphisms did not affect the likelihood of response.

show abstract

Steroid treatment alters adhesion molecule and chemokine expression in experimental acute graft-vs.-host disease of the intestinal tract

Cited by 28 publications

References 67 publications

Advances in graft-versus-host disease biology and therapy

Advances in graft-versus-host disease biology and therapy

Cytostatic conditioning in experimental allogeneic bone marrow transplantation: Busulfan causes less early gastrointestinal toxicity but Treosulfan results in improved immune reconstitution

GLCCI1 and Glucocorticoid Receptor Genetic Diversity and Response to Glucocorticoid-Based Treatment of Graft-versus-Host Disease

Contact Info

Product

Resources

About